Taiwan's ScinoPharm, Foresee Of U.S. To Form Prostate-Cancer Drug JV
This article was originally published in PharmAsia News
Executive Summary
Taiwan's ScinoPharm has agreed contribute $3.6 million and create a joint venture with U.S.-based Foresee Pharmaceutical to develop prostate-cancer drugs.